Evidence map›Paper›PMID 38288106›Full record

ArticleFrontiers in oncology2023

Cloud platform to improve efficiency and coverage of asynchronous multidisciplinary team meetings for patients with digestive tract cancer.

Yu Zhang, Jie Li, Min Liao, Yalan Yang, Gang He, Zuhong Zhou, Gang Feng, Feng Gao, Lihua Liu, Xiaojing Xue and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Ablative Therapies in Low-Risk Thyroid Cancer.Annals of surgical oncology · 2025
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yu ZhangDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Jie LiDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Min LiaoInformation Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Yalan YangDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Gang HeInformation Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Zuhong ZhouInformation Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Gang FengDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Feng GaoDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Lihua LiuDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Xiaojing XueDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Zhongli LiuDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Xiaoyan WangDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Qiuling ShiState Key Laboratory of Ultrasound in Medicine and Engineering, School of Public Health, Chongqing Medical University, Chongqing, China.
Xaiobo DuDepartment of Oncology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology, Mianyang, China.
Mianyang Central Hospital · CNChongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multidisciplinary team (MDT) meetings are the gold standard of cancer treatment. However, the limited participation of multiple medical experts and the low frequency of MDT meetings reduce the efficiency and coverage rate of MDTs. Herein, we retrospectively report the results of an asynchronous MDT based on a cloud platform (cMDT) to improve the efficiency and coverage rate of MDT meetings for digestive tract cancer. Methods: The participants and cMDT processes associated with digestive tract cancer were discussed using a cloud platform. Software programming and cMDT test runs were subsequently conducted to further improve the software and processing. cMDT for digestive tract cancer was officially launched in June 2019. The doctor response duration, cMDT time, MDT coverage rate, National Comprehensive Cancer Network guidelines compliance rate for patients with stage III rectal cancer, and uniformity rate of medical experts' opinions were collected. Results: The final cMDT software and processes used were determined. Among the 7462 digestive tract cancer patients, 3143 (control group) were diagnosed between March 2016 and February 2019, and 4319 (cMDT group) were diagnosed between June 2019 and May 2022. The average number of doctors participating in each cMDT was 3.26 ± 0.88. The average doctor response time was 27.21 ± 20.40 hours, and the average duration of cMDT was 7.68 ± 1.47 min. The coverage rates were 47.85% (1504/3143) and 79.99% (3455/4319) in the control and cMDT groups, respectively. The National Comprehensive Cancer Network guidelines compliance rates for stage III rectal cancer patients were 68.42% and 90.55% in the control and cMDT groups, respectively. The uniformity rate of medical experts' opinions was 89.75% (3101/3455), and 8.97% (310/3455) of patients needed online discussion through WeChat; only 1.28% (44/3455) of patients needed face-to-face discussion with the cMDT group members. Conclusion: A cMDT can increase the coverage rate of MDTs and the compliance rate with National Comprehensive Cancer Network guidelines for stage III rectal cancer. The uniformity rate of the medical experts' opinions was high in the cMDT group, and it reduced contact between medical experts during the COVID-19 pandemic.

Indexed as

cancer treatmentcloud platformdigestive tract cancermultidisciplinary team meetingtreatment planning

Identifiers

PMID38288106
PMCPMC10824572
OpenAlexW4390870733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.